Clinical Trial Update: ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

This update notes the completion of a Phase 2 trial of ABX-EGF as second-line therapy for advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• ABX-EGF (panitumumab)

Snippet

Sponsor: Amgen | Conditions: Non-small Cell Lung Cancer, Neoplasm Metastasis | Phase 2 | Status: COMPLETED